Fluconazole andCandida kruseiFungemia

Publisher Website
Google Scholar
Abstract
Fluconazole, a bis-triazole antifungal agent, has excellent activity in vitro and in vivo against various candida species and is effective in the treatment of oropharyngeal candidiasis in patients with cancer and in patients infected with the human immunodeficiency virus.1 , 2 Although fluconazole has been shown to have activity against experimentally induced Candida albicans fungemia in immunosuppressed mice,3 studies are currently in progress to determine its efficacy both therapeutically and empirically against systemic fungal infection in immunosuppressed humans. Several recent reports have documented the development of resistant strains of candida after the use of fluconazole as a prophylactic agent or as primary therapy for superficial candidiasis.4 5 6